Clinical trials: Advanced Solid Tumors (Phase 1)
Neoplasms, Tumor
A Study of IMC-TR1 in Participants With Advanced Solid Tumors
A study to evaluate the safety and tolerability of anti-TGFβRII monoclonal antibody (IMC-TR1) in participants with advanced solid tumors, as well as gather evidence of anti-tumor activity.
- Trial name
- NCT01646203
- Testing
- IMC-TR1
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer, Prostate Cancer
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
The purpose of this study is to determine if TH-302, in combination with A) Gemcitabine, or B) Docetaxel or C) Pemetrexed methotrexate, are safe and effective in the treatment of Pancreatic Cancer, Castrate-resistant Prostate…
- Conditions
- Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
- Trial name
- NCT00743379
- Testing
- TH-302
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Threshold Pharmaceuticals
HR-positive, HER2-negative Advanced Breast Cancer
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
This study is to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of TYK-00540 as monotherapy or combined with fulvestrant in advanced solid tumors.
- Trial name
- NCT06950086
- Testing
- TYK-00540
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- TYK Medicines, Inc
Unspecified Adult Solid Tumor, Protocol Specific
MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004886
- Testing
- docetaxel, dofequidar fumarate
- Where
- 3 sites in France, Germany
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC)
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- FIT-001 (NCT06026410)
- Testing
- Darlifarnib, Cabozantinib, Adagrasib
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 300 people
- Sponsor
- Kura Oncology, Inc.
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Metastatic Solid Tumors
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of SKB107 in subjects with advanced solid tumors with bone metastases.
- Trial name
- NCT07087197
- Testing
- SKB107 for injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Solid Tumor
A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
The goal of this study is to evaluate the safety of HH-101 antibody, administered as monotherapy to participants with advanced solid tumors.
- Trial name
- NCT07554196
- Testing
- HH-101 (0.3 mg/kg), HH-101 (1 mg/kg ), HH-101 (3 mg/kg )
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Huahui Health
Solid Tumors
Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies
This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety, tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in…
- Trial name
- NCT00413686
- Testing
- AZD7762, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
To assess the safety, tolerability, PK and preliminary efficacy of CD-001 in patients with advanced solid tumors. and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT06801470
- Testing
- CD-001
- Where
- China
- Volunteers
- 137 people
- Sponsor
- CD (Suzhou) Biopharma Co., Ltd.
Advanced/Metastatic Solid Tumors
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.
- Trial name
- NCT03833427
- Testing
- Selumetinib, Pembrolizumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with…
- Trial name
- NCT03347123
- Testing
- Epacadostat, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Incyte Corporation
Solid Tumor of Epithelial Origin, Gastric Cancer
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability profile including the dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of epithelial origin, and of AbGn-7 in…
- Trial name
- NCT01466569
- Testing
- AbGn-7
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 13 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Various Advanced Cancer
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors.
- Trial name
- CheckMate358 (NCT02488759)
- Testing
- Nivolumab, Ipilimumab, Relatlimab
- Where
- 40 sites in United States, Belgium and 9 more
- Volunteers
- 578 people
- Sponsor
- Bristol-Myers Squibb
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
- Trial name
- NCT03425279
- Testing
- CAB-AXL-ADC, PD-1 inhibitor
- Where
- 40 sites in United States, Hong Kong and 1 more
- Volunteers
- 245 people
- Sponsor
- BioAtla, Inc.
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Neoplasms
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
The primary objectives of the study are: To determine the safety and the maximum tolerated dose (MTD) of IPI-926 To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) To recommend a dose…
- Trial name
- NCT00761696
- Testing
- IPI-926
- Where
- 5 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
CLDN6-positive Solid Tumor, Ovarian Cancer
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Before a treatment can be approved for use, clinical studies need to be done. This study is for people with certain types of cancer that have become worse and are difficult to treat.
- Conditions
- CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT06681870
- Testing
- ASP1893
- Sponsor
- Astellas Pharma Global Development, Inc.
Major Advanced Solid Tumors Other Than Colorectal
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
Phase I Study of PM01183 in Non-Colorectal Cancer Patients to determine the recommended dose (RD) of PM01183.
- Trial name
- NCT01405391
- Testing
- PM01183
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- PharmaMar
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.